Stockreport

Silence Therapeutics reports Q3 results [Seeking Alpha]

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Net loss for the three ended September 30, 2024, was £27.0 million, or 19.1 pence basic and diluted net loss per share. More on Silence Therapeutics Silence Therape [Read more]